PT  - JOURNAL ARTICLE
AU  - Bergamaschi, Laura
AU  - Mescia, Federica
AU  - Turner, Lorinda
AU  - Hanson, Aimee
AU  - Kotagiri, Prasanti
AU  - Dunmore, Benjamin J.
AU  - Ruffieux, Hélène
AU  - De Sa, Aloka
AU  - Huhn, Oisín
AU  - Morgan, Michael D
AU  - Gerber, Pehuen Pereyra
AU  - Wills, Mark R.
AU  - Baker, Stephen
AU  - Calero-Nieto, Fernando J
AU  - Doffinger, Rainer
AU  - Dougan, Gordon
AU  - Elmer, Anne
AU  - Goodfellow, Ian G
AU  - Gupta, Ravindra K.
AU  - Hosmillo, Myra
AU  - Hunter, Kelvin
AU  - Kingston, Nathalie
AU  - Lehner, Paul J.
AU  - Matheson, Nicholas J.
AU  - Nicholson, Jeremy K.
AU  - Petrunkina, Anna M.
AU  - Richardson, Sylvia
AU  - Saunders, Caroline
AU  - Thaventhiran, James E.D.
AU  - Toonen, Erik J. M.
AU  - Weekes, Michael P.
AU  - ,
AU  - Göttgens, Berthold
AU  - Toshner, Mark
AU  - Hess, Christoph
AU  - Bradley, John R.
AU  - Lyons, Paul A.
AU  - Smith, Kenneth G.C.
TI  - Delayed bystander CD8 T cell activation, early immune pathology and persistent dysregulation characterise severe COVID-19
AID  - 10.1101/2021.01.11.20248765
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.11.20248765
4099  - http://medrxiv.org/content/early/2021/03/26/2021.01.11.20248765.short
4100  - http://medrxiv.org/content/early/2021/03/26/2021.01.11.20248765.full
AB  - In a study of 207 SARS-CoV2-infected individuals with a range of severities followed over 12 weeks from symptom onset, we demonstrate that an early robust bystander CD8 T cell immune response, without systemic inflammation, is characteristic of asymptomatic or mild disease. Those presenting to hospital had delayed bystander responses and systemic inflammation already evident at around symptom onset. Such early evidence of inflammation suggests immunopathology may be inevitable in some individuals, or that preventative intervention might be needed before symptom onset. Viral load does not correlate with the development of this pathological response, but does with its subsequent severity. Immune recovery is complex, with profound persistent cellular abnormalities correlating with a change in the nature of the inflammatory response, where signatures characteristic of increased oxidative phosphorylation and reactive-oxygen species-associated inflammation replace those driven by TNF and IL-6. These late immunometabolic inflammatory changes and unresolved immune defects may have clinical implications.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe are grateful for the generous support of CVC Capital Partners, the Evelyn Trust (20/75), UKRI COVID Immunology Consortium, Addenbrookes Charitable Trust (12/20A), the NIHR Cambridge Biomedical Research Centre and the UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC) for their financial support for their financial support. K.G.C.S. is the recipient of a Wellcome Investigator Award (200871/Z/16/Z); M.P.W. is the recipient of Wellcome Senior Clinical Research Fellowship (108070/Z/15/Z); C.H. was funded by a Wellcome COVID-19 Rapid Response DCF and the Fondation Botnar; N.M. was funded by the MRC (CSF MR/P008801/1), NHSBT (WPA15-02) and Addenbrookes Charitable Trust (grant ref. to 900239 NJM); I.G.G. is a Wellcome Senior Fellow and was supported by funding from the Wellcome (Ref: 207498/Z/17/Z). P.J.L. is the recipient of a Wellcome Trust Principal Research Fellowship (084957/Z/08/Z) and MRC research grant (MR/V011561/1).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:"NIHR BioResource" REC ref 17/EE/0025, and "Genetic variation AND Altered Leucocyte Function in health and disease - GANDALF" REC ref 08/H0308/176All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesIn progress and we will update when available